Drug Profile
Fisogatinib - CStone Pharmaceuticals
Alternative Names: BLU-554; CS 3008Latest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator Blueprint Medicines
- Developer Blueprint Medicines; CStone Pharmaceuticals
- Class Acrylamides; Amines; Antineoplastics; Chlorobenzenes; Pyrans; Quinazolines; Small molecules
- Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Liver cancer
- Discontinued Cholangiocarcinoma
Most Recent Events
- 28 Feb 2024 Blueprint Medicines Corporation completes a phase I trial in Liver cancer (Inoperable/Unresectable) the US, China, France, Germany, Hong Kong, Italy, South Korea, Singapore, Spain, Switzerland, Taiwan, the UK (PO) (NCT02508467)
- 01 Dec 2022 Pharmacodynamics data from a phase preclinical trial in Hepatocellular carcinoma presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
- 31 Jan 2022 Blueprint Medicines has patents pending for fisogatinib and and other FGFR4 inhibitors in USA and other countries before January 2021